Expertise in
15
conditions

Dr. Ira Dunkel

Hematology | Oncology
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 
Accepting New Patients
Expertise in
15
conditions
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 

Overview

Ira Dunkel is a Hematologist and an Oncologist practicing medicine in New York, New York.

Dr. Dunkel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Retinoblastoma, Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, and Glioma.

He is actively involved in clinical research, co-authoring 138 peer reviewed articles and participating in 17 clinical trials. Dr. Dunkel is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065

Additional Areas of Focus

Dr. Dunkel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drug: Selumetinib
Study Phase: Phase 1/Phase 2
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma
Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Biological
Study Drug: HER2 Specific CAR T Cell
Study Phase: Phase 1
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Device, Combination product
Study Phase: Not Applicable
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2026
Intervention Type: Biological
Study Drug: APX005M
Study Phase: Phase 1
Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma
Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drugs: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, Potassium Iodide, Dexamethasone, Antipyretic, Antihistamine, Anti-Emetics
Study Phase: Phase 2
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Hydroxychloroquine
Study Phase: Phase 1/Phase 2
Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life
Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Behavioral
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drug: INCB7839
Study Phase: Phase 1
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Enrollment Status: Completed
Publish Date: November 20, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 9 Less Clinical Trials

138 Total Publications

Detection and Characterization of RB1 Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test.
Detection and Characterization of RB1 Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test.
Journal: JAMA ophthalmology
Published: May 08, 2025
Similar Doctors
Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology
Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Moskowitz is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses T-Cell Lymphoma, Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology
Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Frequently Asked Questions about Dr. Ira Dunkel

How do I make an appointment with Dr. Ira Dunkel?

You can book an appointment with Dr. Ira Dunkel by calling their office at 917-979-4203. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ira Dunkel a top-rated expert for Retinoblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ira Dunkel is classified as an Elite expert for Retinoblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ira Dunkel specialize in?

While Dr. Ira Dunkel is a Hematology, they have specific expertise in Retinoblastoma, Diffuse Midline Glioma H3 K27M-Mutant, and Brain Stem Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ira Dunkel participate in research or clinical trials?

Yes. Dr. Ira Dunkel has published 138 articles and abstracts on conditions like Retinoblastoma. You can view a list of Dr. Ira Dunkel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ira Dunkel accept my insurance?

Dr. Ira Dunkel accepts most major insurance plans, including Capital District Physicians Health and Humana. We recommend calling the office directly at 917-979-4203 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dunkel's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile